Table 1 Summary of compounds screened from commercial and in-house libraries and structure–activity relationship (SAR) analyses.

From: Discovery of uncompetitive inhibitors of SapM that compromise intracellular survival of Mycobacterium tuberculosis

Library

Number screened

Primary screening (≥ 50% inhibition)

Hits confirmed (≥ 50% inhibition)

IC50 (< 10 µM)

In-house

96

0

–

–

LOPAC-Pfizer

90

1

0

–

Enzo-BML 2834

32

3

1

0

LOPAC-1280

1273

14

5

2

SAR

12

–

4

1

Total

1503

18

10

3

Back to article page